skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Recombinant human epoetin beta in the treatment of chemotherapy-related anemia

Review

(2256) Views  (527) Full article downloads

Authors: Iain RJ Macpherson, Colin R Lindsay, Nicholas S Reed

Published Date March 2009 Volume 2009:5 Pages 261 - 270
DOI: http://dx.doi.org/10.2147/TCRM.S3320

Iain RJ Macpherson, Colin R Lindsay, Nicholas S Reed

Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Abstract: Anemia is a common complication of systemic anti-cancer treatment. In this context epoetin beta, like other erythropoiesis-stimulating agents (ESAs), has demonstrable efficacy in raising Hb concentration and reducing the requirement for red cell transfusion. Consequently ESA therapy has gained increasing prominence in the management of chemotherapy-related anemia. However, recent trial data have suggested a higher rate of thromboembolic events, enhanced tumor progression and reduced survival in some patients with cancer who receive ESA therapy. In response, regulatory authorities have mandated increasingly restrictive label changes. In light of these new developments we consider the current role of epoetin beta in the management of chemotherapy-related anemia.

Keywords: anemia, cancer, erythropoietin, epoetin, chemotherapy






 

Other articles by Dr Iain MacPherson



Readers of this article also read:

Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
Treatment and chemoprevention of NSAID-associated gastrointestinal complications
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
New approaches in the management of advanced breast cancer – role of combination treatment with liposomal doxorubicin
Prevalence of modifiable cardiovascular risk factors in long-term renal transplant patients
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Treatment of anemia in chronic kidney disease: known, unknown, and both
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Mild and moderate pre-dialysis chronic kidney disease is associated with increased coronary artery calcium
Erratum